Design of two phase III open-label trials evaluating ocrelizumab in patients with relapsing-remitting multiple sclerosis and suboptimal response to disease-modifying treatment

---

Bermel R., Comi G., Eralinna J. -., Leist T. P., Nicholas R., Oreja-Guevara C., ...More

32nd Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), London, Canada, 14 - 17 September 2016, vol.22, pp.615-616

• Publication Type: Conference Paper / Summary Text
• Volume: 22
• City: London
• Country: Canada
• Page Numbers: pp.615-616
• Istanbul University Affiliated: Yes